OABI(OABI)
OABI
ANALYST COVERAGE9 analysts
BUY
▲ +83.5%upside to target
PRICE
Prev Close
2.19
Open
2.15
Day Range2.08 – 2.24
2.08
2.24
52W Range1.22 – 2.30
1.22
2.30
89% of range
VOLUME & SIZE
Avg Volume
548.4K
FUNDAMENTALS
P/E Ratio
-4.7x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
TECHNICAL
RSI (14)
62
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 19
DEx-Dividend
In 88 days
Aug 14
PDividend Pay
In 105 days
Aug 31
Key MetricsTTM
Market Cap$259.62M
Revenue TTM$28.91M
Net Income TTM-$54.28M
Free Cash Flow-$26.02M
Gross Margin35.5%
Operating Margin-200.3%
Net Margin-187.7%
Return on Equity-20.3%
Return on Assets-18.5%
Debt / Equity0.07
Current Ratio4.80
EPS TTM$-0.42
OABI News
About
the omniab discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics.
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Bill HarrimanSenior Vice President of Antibody Discovery
Bob ChenSenior Vice President of Discovery Systems
Christel IfflandSenior Vice President of Antibody Technologies
Yasmina Noubia AbdicheSenior Vice President of Exploratory Research
Charles S. BerkmanChief Legal Officer & Secretary
Kurt A. GustafsonExecutive Vice President of Finance & Chief Financial Officer
Matthew W. FoehrPresident, Chief Executive Officer & Director
Todd PettingillVice President of Business Development & Strategy
Cia McCaffreySenior Vice President of People & Talent